YBII Postdoctoral Program

Shubham Bansal is a Postdoctoral Associate in the Department of Radiology & Biomedical Imaging at the Yale School of Medicine. His doctoral research focuses on advancing drug discovery and targeted drug delivery systems, with specific expertise in reactive oxygen species (ROS), gaseous signaling molecules, and click chemistry. Dr. Bansal earned both his PhD and MS in Chemistry from Georgia State University. Throughout his academic career, his work has been recognized with numerous distinctions, including the David W. Boykin Graduate Fellowship in Medicinal Chemistry and the Center for Diagnostics and Therapeutics “Fellow of the Year” award. He is a co-inventor of a pending patent for redox-sensitive prodrugs, and his research is widely published in high-impact scientific journals, including the Journal of Medicinal Chemistry, Chemical Science, and Analytical Chemistry.

Dr. Hyunjae Kim is currently a Postdoctoral Associate in the Department of Biomedical Informatics & Data Science at Yale University School of Medicine. He was selected as a 2026 awardee of the Yale Biomedical Imaging Institute (YBII) Postdoctoral Funding Program. Prior to this, he earned his Ph.D. in Computer Science from Korea University in 2023, where he also served as a Postdoctoral Researcher from 2023 to 2024. Dr. Kim specializes in natural language processing, medical foundation models, and multimodal learning. His research focuses on developing AI models that learn from and reason across multimodal biomedical data, with particular interests in the retrieval and reliable use of biomedical evidence and in the development of large-scale biomedical datasets and resources. An active contributor to the AI research community, Dr. Kim serves as an area chair and reviewer for leading international conferences such as AAAI, ACL, EMNLP, NAACL, and NeurIPS. He also reviews for top-tier journals including Nature, Nature Biomedical Engineering, and ACM Computing Surveys. Dr. Kim has been recognized for his top-ranked performance in international biomedical AI competitions, including BioCreative VII, BioASQ 11b, and the BioNLP Workshop-RadSum23. His work has been published in prominent venues such as AAAI, ACL, EACL, EMNLP, NAACL, npj Digital Medicine, and Nature Communications, contributing to advances in AI methods and their application to real-world problems in biomedicine and healthcare.

I received my Ph.D. in Biological Sciences from the CSIR–Indian Institute of Integrative Medicine (CSIR-IIIM)/AcSIR, India, in 2023. My doctoral research in pharmacology focused on targeting NLRP3 inflammasome-mediated inflammation in sickle cell disease and AD. I joined Rangaraju Lab as a postdoc in October 2023. My research interests center on understanding the mechanisms of neuroinflammation and neurodegeneration in AD. In the Rangaraju lab, I have characterized the interactome of Kv1.3 channels in T cells and conducted comparative analyses that revealed context-dependent functions of Kv1.3 potassium channel in microglia and T cells. My current work investigates the molecular and pathological consequences of microglia-specific ERK hyperactivation in neuroinflammation, with the goal of identifying therapeutic targets and biomarkers for AD.

Postdoctoral Associate